Purpose: The influence of tumor location on survival was investigated in patients with lung cancer who received radical chemoradiotherapy. Methods: We examined the relationships between radiation site and survival outcome in patients with lung cancer. A total of 14,640 patients with lung cancer who received radical chemoradiotherapy for stage I-III disease were reviewed from Surveillance, Epidemiology, and End Results Program (SEER) datasets. We further retrospectively collected cases from a cohort of 148 eligible patients diagnosed between December 2013 and December 2019. Results: Female sex, adenocarcinoma, and stage III disease were significantly correlated with right lung lobe tumor. Advanced age at diagnosis was associated with lower lung tumor origin. For the patients who received radical chemoradiotherapy, 1- and 3-year survival rates were 56.5% and 22.9%. Lower lobe origin was closely related to a shorter overall survival compared to non-right lower lobe tumors (p < 0.001). We also validated the difference in our cohort (p = 0.004). Conclusions: Our results suggest that lower lobe tumor increases mortality risk in patients with lung cancer treated with radical chemoradiotherapy.
基金:
China NSFCNational Natural Science Foundation of China (NSFC) [81672984, 82003310]; Foundation of Tongji Hospital [2018A02]
第一作者单位:[1]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Oncol, 1095 Jiefang Ave, Wuhan 430030, Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
Liu Fangfang,Yuan Xun,Jiang Jizong,et al.Lower lobe origin is related to unfavorable outcomes in patients with stage I-III lung cancer treated with radical chemoradiotherapy[J].TUMORI JOURNAL.2021,107(5):400-406.doi:10.1177/0300891620971359.
APA:
Liu, Fangfang,Yuan, Xun,Jiang, Jizong,Zhang, Peng,Chen, Yuan&Chu, Qian.(2021).Lower lobe origin is related to unfavorable outcomes in patients with stage I-III lung cancer treated with radical chemoradiotherapy.TUMORI JOURNAL,107,(5)
MLA:
Liu, Fangfang,et al."Lower lobe origin is related to unfavorable outcomes in patients with stage I-III lung cancer treated with radical chemoradiotherapy".TUMORI JOURNAL 107..5(2021):400-406